An oncologist and NIH-funded T-cell researcher said that without adequate indirect funding, labs will shrink, clinical trials will stall, and life-saving innovations will be lost.; An oncologist and NIH-funded T-cell researcher said that without adequate indirect funding, labs will shrink, clinical trials will stall, and life-saving innovations will be lost.
